PNAS Therapeutics

PNAS Therapeutics is developing a one-step drug delivery platform for next-generation regenerative therapies to cure insulin-dependent diabetes. Its breakthrough approach reprograms existing pancreatic alpha cells into functional insulin-producing beta cells, offering a one-time curative treatment. Backed by Innovate UK grants, it's advancing its lead program toward clinical trials, transforming diabetes care with platform technology applicable across multiple conditions.